In AML, mutations in CEBPA, NPM1, FLT3, RUNX1, ASXL1, and TP53 have shown prognostic relevance and have been incorporated into the 2017 ELN risk stratification.6 This evidence concerns the gene TP53 and acute myeloid leukemia.